GE HealthCare Technologies Inc. (GEHC) SEC Filings & Earnings Calls

Leadership transition risk; details of departure not disclosed in excerpt

“Item 5.02 filed but body excerpt lacks details on the executive change”

Patient Care Solutions segment continues to underperform with revenue decline and negative EBIT; strategic review may lead to divestiture or restructuring

“Patient Care Solutions (PCS) financial performance continued to be challenged. In Patient Care Solutions, while we are focused on returning the business to growth and profitability, we are reviewing strategic options to maximize its long-term value”

Inflation in memory chips, oil and freight costs pressuring margins; $250M inflation headwind expected for FY2026

“Continue to expect approximately $250 million of inflation associated with memory chips, oil and freight and other components” · word for word

Tariff cost pressure

“Tariffs negatively impacted our Operating income by $68 million and $156 million for the three and six months ended June 30, 2026, respectively.” · word for word

PCS segment operational challenges

“PCS segment revenues were $675 million, decreasing 13.3% or $104 million, primarily driven by operational and fulfillment challenges.” · word for word

China market headwinds

“we continue to monitor developments in the China market, including increased competition from local companies and the prevalence of volume based procurement policies, both of which have impacted our orders and revenues and may continue to do so.” · word for word

Geopolitical instability

“Global geopolitical instability, including the conflict in the Middle East, adversely impacted our costs, supply chains, and logistics during the second quarter of 2026.” · word for word

CFO transition introduces temporary leadership uncertainty, but interim CFO has deep company experience.

“CFO resignation for external role, interim CFO appointed with 38 years of finance experience.”

Preliminary results subject to change upon completion of quarterly closing.

“These preliminary results are not a comprehensive statement of the Company's financial results for the quarter ended June 30, 2026, and should not be viewed as a substitute for financial statements prepared in accordance with U.S. GAAP.” · word for word

Inflation in memory chips, oil, and freight costs pressuring margins and profit outlook.

“We saw significant increases in memory chips, oil and freight costs during the first quarter that we assume will impact the rest of 2026.” · word for word

Patient Care Solutions segment revenue decline of 6.5% YoY indicates potential structural weakness.

“Patient Care Solutions Segment Revenues $704 YoY % change (6.5)%”

PDx supplier issue resolved but caused one-time profitability hit.

“Profitability in the first quarter was impacted by a PDx supplier issue that has since been resolved.” · word for word

Tariff cost pressure

“tariffs materially impacted our Operating income by approximately $90 million and cash flows by approximately $110 million for the three months ended March 31, 2026” · word for word

China market headwinds

“China region revenues were $567 million, decreasing 4.4% or $26 million with declines in Imaging and AVS revenues” · word for word

Cost inflation and supplier issues

“Cost of products sold increased $320 million or 530 basis points as a percent of Sales of products. The increase as a percent of sales was largely driven by cost inflation, including the impact of incremental tariffs, investment in design follow-through, and a PDx supplier issue.” · word for word

Tariff exposure on imported components

“Earnings per share grew, driven by healthy volume and ongoing productivity improvements, even with tariff impact, a testament to the significant mitigation work undertaken by our team.” · word for word

PCS segment underperformance

“PCS Adjusted EBIT ($M) 30% Weight Threshold $339 Target $399 Max $459 Actual $221 Bonus Performance Metric Payout —%”

No material change in leverage; facility size unchanged.

“New facility replaces prior facility of same size; no increase in debt capacity.”

China anti-corruption campaign impact

“In 2023, China’s Central Commission for Discipline Inspection, the National Supervisory Commission, and other governmental entities in China initiated an anti-corruption campaign focused on the healthcare sector, which contributed to delayed orders and sales in our China business.” · word for word

Tariff expense negatively impacted margins; company mitigated gross impacts but remains exposed.

“Tariff expense and unfavorable mix impacted margins; company significantly mitigated gross tariff impacts.”

Increased leverage from $2.0B debt raise; covenants include maximum leverage ratio.

“Term Loan Credit Agreement includes maximum permitted leverage ratio covenant.”

Increased debt load, though likely refinancing; no material change in risk profile.

“Offering of $1.25B in senior notes”

Tariff cost pressure

“tariffs materially impacted our current year profitability and cash flows, primarily the bilateral U.S. and Chinese tariffs and U.S. tariffs on all other global import suppliers.” · word for word

China demand slowdown

“China region revenues were $547 million, decreasing 3% or $17 million due to a decrease in AVS and PCS revenues” · word for word

PCS product hold

“PCS segment revenues were $731 million, decreasing 6% or $48 million, primarily driven by a product hold” · word for word

Tariffs are a significant headwind, impacting margins and EPS. Detailed tariff assumptions provided, with escalation expected.

“Guidance includes approximate tariff impacts of $265 million to Adjusted EBIT* and $0.45 to Adjusted EPS*... Tariff assumptions for updated guidance: Bilateral U.S. and China tariffs introduced this year continue and will rise on November 10, 2025 (to a rate of 54% for U.S. tariffs imposed on goods imported from China to the U.S. and to 34% for Chinese tarif” · word for word

Patient Care Solutions segment revenue declined 6% (organic -7%) and EBIT margin dropped 680 bps to 3.7%.

“Patient Care Solutions... Segment Revenues $731... YoY % change (6)%... YoY % Organic* change (7)%... Segment EBIT Margin 3.7%... YoY change (680) bps”